Medicines Marketed by Cadila Pharmaceuticals Ltd

About Cadila Pharmaceuticals Ltd

Cadila Pharmaceuticals Ltd is a renowned player in the pharmaceutical sector, with a rich history dating back to 1951. Founded by Indravadan A. Modi and his childhood friend Ramanbhai Patel, the company has grown into a global entity, serving consumers in over 100 countries, including the USA, Europe, Japan, and Africa. With its headquarters in Ahmedabad, India, Cadila Pharmaceuticals Ltd has established a strong presence in the international market.

Cadila Pharmaceuticals Ltd boasts a diverse and dedicated workforce of more than 9,000 employees, spanning multiple cultures, languages, and nationalities. The company's manufacturing facilities are strategically located in Dholka and Samba, India, as well as Addis Ababa, Ethiopia. These state-of-the-art facilities adhere to the highest global standards, with the Dholka and Ankleshwar sites being USFDA-certified and the Ethiopia facility being WHO-cGMP compliant.

Cadila Pharmaceuticals Ltd Products

Cadila Pharmaceuticals Ltd offers a comprehensive range of pharmaceutical products, catering to various therapeutic areas. The company's portfolio includes Active Pharmaceutical Intermediates (APIs) manufactured at its Ankleshwar facility, finished formulations such as tablets and capsules produced at Dholka and Samba, food supplements, biotechnology products, and pharmaceutical machinery through its Karnavati Engineering division. This diverse product range enables Cadila Pharmaceuticals Ltd to meet the varied needs of its global customer base.

Among its most popular and innovative offerings are Natural Streptokinase and Hyaluronic Acid products, for which Cadila Pharmaceuticals Ltd is the sole Indian manufacturer. The company also takes pride in introducing groundbreaking formulations like world's first Rabeprazole in IV form, the first boosted-Rifampicin fixed-dose combination for Tuberculosis treatment, and a medicine combination for preventing Cardiovascular Diseases. Other notable products include medications for Non-Small Cell Lung Cancer treatment and quadrivalent influenza vaccine approved by the medicines Controller General of India (DCGI) in 2024. Cadila Pharmaceuticals Ltd's product cater to various therapeutic areas, ensuring comprehensive healthcare solutions for patients worldwide.